Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 19/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24047518 | 1.00 | NAMPT (0.46) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL24047142 | 0.92 | ALDH1A1 (0.44) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL25926224 | 0.89 | NAMPT (0.37) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL24047514 | 0.87 | DHODH (0.54) | NAMPTCYP2C9 | |
| SCHEMBL25332249 | 0.87 | MEN1 (0.44) | NAMPTCYP2C9 | |
| SCHEMBL30216788 | 0.85 | ALDH1A1 (0.48) | NAMPT | |
| SCHEMBL24049604 | 0.85 | ALDH1A1 (0.48) | NAMPT | |
| SCHEMBL24048146 | 0.85 | HDAC3 (0.44) | NAMPT | |
| SCHEMBL24047489 | 0.85 | DHODH (0.44) | NAMPTCYP2C9 | |
| SCHEMBL24047623 | 0.85 | RAB9A (0.43) | NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153577-A1 | NEW MALONITRILE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | claimed |
| CN-115551837-A | Novel malononitrile derivatives | 豪夫迈·罗氏有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-20230242494-A1 | MALONITRILE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4153577-A1 | NEW MALONITRILE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| CN-115551837-A | Novel malononitrile derivatives | 豪夫迈·罗氏有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242494-A1 | MALONITRILE DERIVATIVES | MAL2, ME1, C5 | NAMPT 443/4885ABCC9 874/4885ABCC8 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.